A Study of Apalutamide in Participants With High-Risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS), as compared to placebo plus ADT.
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
- ClinicalTrials.gov Identifier: NCT03767244
- Protocol Number: 19-140
- Principal Investigator: Glenn Bubley
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required